Drug Profile
Bavisant - BenevolentAI/Johnson & Johnson
Alternative Names: Bavisant; BEN-2001; JNJ-1074; JNJ-31001074Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Johnson & Johnson
- Developer BenevolentAI; Johnson & Johnson
- Class Morpholines; Neuropsychotherapeutics; Piperazines; Sleep disorder therapies; Small molecules
- Mechanism of Action Histamine H3 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Attention-deficit hyperactivity disorder; Narcolepsy
Most Recent Events
- 25 Jul 2022 Discontinued - Phase-I for Attention-deficit hyperactivity disorder (In adolescents, In children) in USA (PO) Johnson & Johnson website, July 2022
- 25 Jul 2022 Discontinued - Phase-II for Attention-deficit hyperactivity disorder in USA (PO) (Johnson & Johnson website, July 2022)
- 25 Jul 2022 Discontinued - Phase-II for Narcolepsy in United Kingdom, Spain, USA, Germany, Czech Republic (PO) (Johnson & Johnson website, July 2022)